# CarryForward Unresolved3 Multi-Module / Note / PDF Reaudit Report

Generated: `2026-06-22`  
Coverage: the remaining unresolved confirmed-core carry-forward slice in flat master-list row order after `CarryForward05`: `ASD-0054`, `ASD-0097`, `ASD-0112`.  
Mode: plan-defined multi-agent closeout using `Evidence-Agent-A/B/C`, `Classification-Reviewer`, `Writeback-Agent-1/2/3`, and single-writer `Main Controller`.

## 1. 本次落地范围

- 本次直接落地 `2` 篇：
  - `ASD-0097`
  - `ASD-0112`
- 本次继续保守挂起 `1` 篇：
  - `ASD-0054`

## 2. 结果概览

- closed records in this carry-forward slice: `2`
- conservative carry-forward records remaining open: `1`
- newly archived local PDFs in this slice: `0`
- notes updated: `2`
- master rows updated: `2`
- explicit safety carry-forward kept visible: `ASD-0054`
- current relaxed top-line change from this round:
  - expanded assignment count: `554`
  - independent `01.04` bucket count: `11`
  - module `03` expanded count: `86`
  - module `07` expanded count: `76`

## 3. Record-Level Outcomes

| ID | Final modules or bucket | PDF / source status | Closeout note |
|---|---|---|---|
| ASD-0097 | `06;07` | no local PDF; Nature full text unavailable in current environment; bioRxiv PDF `403` | accepted `06` core plus source-limited `07` adjunct from human-biomedical case studies |
| ASD-0112 | `03;07` | no local PDF; ScienceDirect full text/PDF unavailable in current environment | accepted `03` core plus source-limited `07` adjunct from COVID-target-linked drug-design validation cases |

## 4. 关键边界说明

`ASD-0097`  
这条本轮完成的是从旧的单模块 `06` 口径正式落地到当前的 `06;07`。新的直接证据虽然仍然不是全文 PDF，而是 Nature Methods DOI landing / preview、data-availability 线索、官方 GitHub README，以及 bioRxiv DOI / PDF 尝试失败记录，但这些一手来源已经足以证明论文不只是在做抽象的 computational biology workflow，而是报告了 COVID-19、human endometrium 与 brain aging 等 human-biomedical case studies。按当前 relaxed multi-module rule，`06` 继续作为稳定核心模块，`07` 可以作为 `source_limited=yes` 的 adjunct module 落地。

`ASD-0112`  
这条本轮完成的是从旧的 `07` 单锚定口径正式落地为 `03;07`。当前可访问的一手来源包括 DOI landing、Elsevier Linkinghub / XML coredata 和 HKUST abstract page。它们已经明确把对象锚定在 `drug molecules`、`chemical space of drug molecules` 和 `multi-objective molecular optimization` 上，因此 `03` 是稳定核心；同时论文还报告了与 COVID-19-related targets 相联系的两组 drug-design validation cases，所以 `07` 可以按当前规则作为 source-limited adjunct module 接受，而不必继续无限期保守挂起。

`ASD-0054`  
这条继续保持显式 safety carry-forward。本轮仍然没有进行新的安全可接受一手访问，因此不能把旧轮已知的 `07;06` lead 伪装成本轮新鲜裁决。进度表、边界队列和本报告都继续把它明确写成 `not accessed due to safety`。

## 5. Conservative Carry-Forward

| ID | Current hold reason | Current status |
|---|---|---|
| ASD-0054 | explicit `not accessed due to safety`; this turn intentionally preserved the safety skip rather than attempting new access | keep conservative |

## 6. PDF Archive Results

- `0/2` landing papers obtained a newly archived local PDF in this slice.
- Non-safety archive / access limitations:
  - `ASD-0097`: Nature full text unavailable in current environment; bioRxiv PDF returned `403`
  - `ASD-0112`: ScienceDirect full text / PDF unavailable in current environment

## 7. Multi-Agent Audit Trace

- `Evidence-Agent-A` covered:
  - `ASD-0054`
  - key pressure point: explicit safety carry-forward only; no fresh first-hand access
- `Evidence-Agent-B` covered:
  - `ASD-0097`
  - key pressure point: `06` stable, `07` support increased enough to land as source-limited adjunct module
- `Evidence-Agent-C` covered:
  - `ASD-0112`
  - key pressure point: `03` stable from chemical-space object evidence, `07` acceptable as source-limited adjunct module
- `Classification-Reviewer` returned:
  - direct landings: `ASD-0097`, `ASD-0112`
  - conservative hold: `ASD-0054`
  - explicit safety-skip row: `ASD-0054`
- `Writeback-Agent-1/2/3` returned disjoint ownership with no overlap; the third slice was empty by design

## 8. 本次后累计进度

- Total unresolved carry-forward rows before this round: `3`
- Closed in this round: `2`
- Remaining unresolved after this round: `1`
- Remaining unresolved IDs after this round:
  - `ASD-0054`
